Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030. covering key aspects of the industry and identifying future growth opportunities.
To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Table of Contents
TABLE OF CONTENTS
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Continuous Manufacturing
3.3. Continuous Manufacturing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of Continuous Manufacturing
3.3.3. Anticipated Shift to Continuous Manufacturing
3.3.4. Advantages of Continuous Manufacturing
3.3.5. Key Challenges Associated with Continuous Manufacturing
3.3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companies with Expertise in Continuous Manufacturing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Manufacturing
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Location of Headquarters
4.2.6. Analysis by Location of Continuous Manufacturing Facilities
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Continuous Manufacturing Related Service
4.2.9. Analysis by Type of Dosage Form
4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.11. Information on Production Capacity
4.2.12. Logo Landscape: Analysis by Year of Establishment and Company Size
4.2.13. Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form
4.2.14. Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule
5. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview
5.2.2. Service Portfolio
5.2.3. Continuous Manufacturing Capabilities and Facilities
5.2.4. Recent Developments and Future Outlook
5.3. Cambrex
5.3.1. Company Overview
5.3.2. Service Portfolio
5.3.3. Continuous Manufacturing Capabilities and Facilities
5.3.4. Recent Developments and Future Outlook
5.4. Patheon
5.4.1. Company Overview
5.4.2. Service Portfolio
5.4.3. Continuous Manufacturing Capabilities and Facilities
5.4.4. Recent Developments and Future Outlook
5.5. SK biotek
5.5.1. Company Overview
5.5.2. Service Portfolio
5.5.3. Continuous Manufacturing Capabilities and Facilities
5.5.4. Recent Developments and Future Outlook
6. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES
6.1. Chapter Overview
6.2. Ajinomoto Bio-Pharma Services
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Continuous Manufacturing Capabilities and Facilities
6.2.4. Recent Developments and Future Outlook
6.3. Almac
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Continuous Manufacturing Capabilities and Facilities
6.3.4. Recent Developments and Future Outlook
6.4. Boehringer Ingelheim BioXcellence™
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Continuous Manufacturing Capabilities and Facilities
6.4.4. Recent Developments and Future Outlook
6.5. CordonPharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Continuous Manufacturing Capabilities and Facilities
6.5.4. Recent Developments and Future Outlook
6.6. Hovione
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Continuous Manufacturing Capabilities and Facilities
6.6.4. Recent Developments and Future Outlook
6.7. Lonza
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Continuous Manufacturing Capabilities and Facilities
6.7.4. Recent Developments and Future Outlook
7. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. Chapter Overview
7.2. Kaneka
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Continuous Manufacturing Capabilities and Facilities
7.2.4. Recent Developments and Future Outlook
7.3. WuXi AppTec
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Continuous Manufacturing Capabilities and Facilities
7.3.4. Recent D
- A sanitation worker became the first Indian to receive a Covid vaccine as the country began the worlds largest inoculation drive.
- Beginners and professionals attain the Security Access Manager V9.0 C2150-609 Certification Exam to grow their careers
- Vision and inspection systems are also known as machine vision systems. Idaho group universities designed a solution to
- 100% real and updated exam questions with answers for all famous certifications. Pass in first attempt .Error Free Products with 24/7 Customer Support.Special discount offer for all customer